Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients
Abstract Objective Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resista...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02130-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390026737057792 |
|---|---|
| author | Yong Ma Zhihua Cao Jiacheng Zhang Xu Zhu Zhonghao Zhao Jinguo Xiong |
| author_facet | Yong Ma Zhihua Cao Jiacheng Zhang Xu Zhu Zhonghao Zhao Jinguo Xiong |
| author_sort | Yong Ma |
| collection | DOAJ |
| description | Abstract Objective Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resistant prostate cancer (mCRPC) patients. Methods Seventy-two mCRPC patients who underwent abiraterone plus prednisone therapy were included in this retrospective study, followed by the serum CDC42 level determination at baseline and month 2 (M2). Additionally, serum CDC42 was detected in thirty age-matched healthy controls (HCs). Results The CDC42 level was higher in mCRPC patients versus HCs [median (interquartile range): 1012.5 (655.8–1671.3) versus 606.0 (392.0–1007.0) pg/mL] (P < 0.001). Meanwhile, the CDC42 level was associated with lymph node metastasis (P = 0.041) and visceral metastasis (P = 0.005), but not other clinical characteristics (P > 0.050) in mCRPC patients. Additionally, the CDC42 level was decreased after 2-month treatment (P < 0.001). Inspiringly, shorter radiographic progression-free survival (rPFS) was observed in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at baseline (P = 0.035). Furthermore, shorter rPFS (P = 0.002) and overall survival (P = 0.043) were discovered in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at M2. More importantly, CDC42 at M2 (> 1000 vs. ≤ 1000 pg/mL) was independently associated with shorter rPFS in mCRPC patients (P = 0.035, hazard ratio = 2.203). Conclusion The serum CDC42 level associates with LNM, visceral metastasis, and worse prognosis in mCRPC patients underwent abiraterone plus prednisone therapy. However, future prospective, large-scale, and controlled studies are needed for validation. |
| format | Article |
| id | doaj-art-1f4dc78954d641c5a317e13fc9ef1a47 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-1f4dc78954d641c5a317e13fc9ef1a472025-08-20T03:41:47ZengSpringerDiscover Oncology2730-60112025-03-0116111010.1007/s12672-025-02130-0Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patientsYong Ma0Zhihua Cao1Jiacheng Zhang2Xu Zhu3Zhonghao Zhao4Jinguo Xiong5Department of Urology, Shanghai Songjiang District Sijing HospitalDepartment of Urology, Shanghai Songjiang District Sijing HospitalDepartment of Urology, Shanghai Songjiang District Sijing HospitalDepartment of Urology, Shanghai Songjiang District Sijing HospitalDepartment of Urology, Shanghai Songjiang District Sijing HospitalDepartment of Urology, Shanghai Songjiang District Sijing HospitalAbstract Objective Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resistant prostate cancer (mCRPC) patients. Methods Seventy-two mCRPC patients who underwent abiraterone plus prednisone therapy were included in this retrospective study, followed by the serum CDC42 level determination at baseline and month 2 (M2). Additionally, serum CDC42 was detected in thirty age-matched healthy controls (HCs). Results The CDC42 level was higher in mCRPC patients versus HCs [median (interquartile range): 1012.5 (655.8–1671.3) versus 606.0 (392.0–1007.0) pg/mL] (P < 0.001). Meanwhile, the CDC42 level was associated with lymph node metastasis (P = 0.041) and visceral metastasis (P = 0.005), but not other clinical characteristics (P > 0.050) in mCRPC patients. Additionally, the CDC42 level was decreased after 2-month treatment (P < 0.001). Inspiringly, shorter radiographic progression-free survival (rPFS) was observed in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at baseline (P = 0.035). Furthermore, shorter rPFS (P = 0.002) and overall survival (P = 0.043) were discovered in mCRPC patients with CDC42 > 1000 pg/mL than in those with CDC42 ≤ 1000 pg/mL at M2. More importantly, CDC42 at M2 (> 1000 vs. ≤ 1000 pg/mL) was independently associated with shorter rPFS in mCRPC patients (P = 0.035, hazard ratio = 2.203). Conclusion The serum CDC42 level associates with LNM, visceral metastasis, and worse prognosis in mCRPC patients underwent abiraterone plus prednisone therapy. However, future prospective, large-scale, and controlled studies are needed for validation.https://doi.org/10.1007/s12672-025-02130-0Cell division cycle 42Metastatic castration-resistant prostate cancerAbiraterone plus prednisoneClinical characteristicsPrognosis |
| spellingShingle | Yong Ma Zhihua Cao Jiacheng Zhang Xu Zhu Zhonghao Zhao Jinguo Xiong Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients Discover Oncology Cell division cycle 42 Metastatic castration-resistant prostate cancer Abiraterone plus prednisone Clinical characteristics Prognosis |
| title | Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients |
| title_full | Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients |
| title_fullStr | Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients |
| title_full_unstemmed | Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients |
| title_short | Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients |
| title_sort | serum cdc42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration resistant prostate cancer patients |
| topic | Cell division cycle 42 Metastatic castration-resistant prostate cancer Abiraterone plus prednisone Clinical characteristics Prognosis |
| url | https://doi.org/10.1007/s12672-025-02130-0 |
| work_keys_str_mv | AT yongma serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients AT zhihuacao serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients AT jiachengzhang serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients AT xuzhu serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients AT zhonghaozhao serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients AT jinguoxiong serumcdc42levelchangeduringabirateroneplusprednisonetreatmentanditsassociationwithprognosisinmetastaticcastrationresistantprostatecancerpatients |